Projected Earnings Date: 2025-07-31    (Delayed quote data   2025-07-11)
Last
 16.47
Change
 ⇓ -0.08   (-0.48%)
Volume
  1,228,814
Open
 16.39
High
 16.60
Low
 16.25
8EMA (Daily)
 15.73
40EMA (Daily)
 15.81
50EMA (Daily)
 16.06
STO (Daily)
 87.758
MACD Hist (Daily)
 0.594
8EMA (Weekly)
 15.677
40EMA (Weekly)
 16.35
50EMA (Weekly)
 16.02
STO (Weekly)
 22.948
MACD Hist (Weekly)
 -0.572
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com